- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04913805
Matching Perfusion and Metabolic Activity in HFpEF (MPMA)
Study Overview
Status
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Payman Zamani, MD
- Phone Number: (215) 615-0800
- Email: payman.zamani@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Contact:
- Nicole Tafuna'i
- Phone Number: 801-831-1044
- Email: Nicole.Tafunai@Pennmedicine.upenn.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- NYHA Class II-III symptoms
- Left ventricular ejection fraction >= 50%
- Stable medical therapy for at least 1 month
Prior or current evidence for elevated filling pressures as follows:
a. Mitral early (E)/mitral septal tissue annular (e') velocity ratio > 8, in the context of a septal e' velocity <=7, in addition to one of the following: i. Large left atrium (LA volume index > 34 mL/m2) ii. Chronic loop diuretic use for control of symptoms iii. Elevated natriuretic peptides within the past year (e.g. NTproBNP > 125 pg/mL in sinus rhythm or > 375 pg/mL if in atrial fibrillation) b. Mitral E/e' ratio > 14 at rest or during exercise c. Elevated invasively-determined filling pressures previously (resting left ventricular end-diastolic pressure >= 16 mm Hg or pulmonary capillary wedge pressure >= 15 mmHg; or PCWP/LVEDP >= 25 mmHg with exercise) d. Prior episode of acute heart failure requiring IV diuretics
Exclusion Criteria:
- Age <18 years old
- Pregnancy:
- Treatment with organic nitrates or phosphodiesterase inhibitors that cannot be interrupted
- Uncontrolled atrial fibrillation, as defined by a resting heart rate > 100 beats per minute at the time of the baseline assessment
- Hemoglobin < 10 g/dL
- Subject inability/unwillingness to exercise
- Moderate or greater left sided valvular disease (mitral regurgitation, aortic stenosis, aortic regurgitation), mild or greater mitral stenosis, severe right-sided valvular disease
- Known hypertrophic, infiltrative, or inflammatory cardiomyopathy
- Clinically significant pericardial disease, as per investigator judgment
- Current angina due to clinically significant epicardial coronary disease, as per investigator judgment
- Acute coronary syndrome or coronary intervention within the past 2 months
- Primary pulmonary artery hypertension (WHO Group 1 Pulmonary Arterial Hypertension)
- Clinically significant lung disease as defined by: Chronic Obstructive Pulmonary Disease meeting Stage III or greater GOLD criteria (FEV1<50%), treatment with oral steroids within the past 6 months for an exacerbation of obstructive lung disease, current use of supplemental oxygen aside from nocturnal oxygen for the treatment of obstructive sleep apnea, desaturation to <90% on the baseline maximal effort cardiopulmonary exercise test
- Clinically-significant ischemia, as per investigator's judgement, on stress testing without either (1) subsequent revascularization, (2) an angiogram demonstrating the absence of clinically significant epicardial coronary artery disease, as per investigator judgment; (3) a follow-up 'negative' stress test, particularly when using a more specific technique (i.e., a negative perfusion imaging test following a 'positive' ECG stress test)
- Left ventricular ejection fraction < 45% on a prior echocardiogram or cardiac MRI
- Significant liver disease impacting synthetic function or volume control (ALT/AST > 3x ULN, Albumin < 3.0 g/dL)
- eGFR < 30 mL/min/1.73m^2
- Methemoglobin > 5%
- Serum potassium > 5.0 mEq/L
- Severe right ventricular dysfunction
- Baseline resting seated systolic blood pressure > 180 mmHg or < 100 mmHg
- Orthostatic blood pressure response to the transition from supine to standing (>20 mmHg reduction in systolic blood pressure 2-3 minutes after standing)
- Active participation in another study that utilizes an investigational agent (observational studies/registries allowed)
- Any condition that, in the opinion of the investigator, will interfere with the performance and completion of the study.
- Contraindications to MRI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Potassium Nitrate
Potassium Nitrate (KNO3) 6 mmol three times daily
|
Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
Other Names:
|
Active Comparator: Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside
Potassium Nitrate (KNO3) 6 mmol three times daily + Propionyl-L-Carnitine (PLC) 1000 mg twice daily + Nicotinamide Riboside (NR) 300 mg three times daily
|
Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
Other Names:
|
Placebo Comparator: Potassium Chloride
Potassium Chloride (KCl) 6 mmol three times daily
|
Active control
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Submaximal Exercise Endurance
Time Frame: week 6
|
Time to exhaustion while exercising at 75% of peak workload
|
week 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skeletal muscle oxidative capacity
Time Frame: week 6
|
MRI assessment of skeletal muscle oxidative phosphorylation capacity
|
week 6
|
Vasodilatory Reserve
Time Frame: week 6
|
Percent change in systemic vascular resistance at baseline vs exhaustion
|
week 6
|
Kansas City Cardiomyopathy Questionnaire Overall Summary Score
Time Frame: week 6
|
Assess the impact of our interventions on quality of life
|
week 6
|
VO2 Kinetics
Time Frame: week 6
|
Assess the impact of our interventions on the kinetics of oxygen consumption (VO2 kinetics) during exercise and recovery "On" and "Off" kinetics will be modeled during the submaximal exercise transient
|
week 6
|
Peak VO2
Time Frame: week 6
|
maximal rate of oxygen consumption determined during the last 30s of exercise.
|
week 6
|
Steps per day
Time Frame: week 6
|
we will use actigraphy to document the average number of steps taken per day during the final week of each interventional period.
Assess the impact of our interventions on ambulatory physical activity
|
week 6
|
Skeletal muscle perfusion
Time Frame: week 6
|
MRI assessment of skeletal muscle oxidative phosphorylation capacity
|
week 6
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Skeletal Muscle Oxidative Capacity
Time Frame: <4 hours in between MRIs
|
The change in MRI skeletal muscle oxidative phosphorylation capacity between assessments while breathing room air versus 100% inspired oxygen
|
<4 hours in between MRIs
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 844627
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure With Preserved Ejection Fraction
-
University Hospital, AkershusNovartisActive, not recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionNorway
-
University of SienaEuropean Association of Cardiovascular ImagingActive, not recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection FractionSpain, Greece, Turkey, Portugal, Australia, Belgium, Italy, Mexico, Netherlands, North Macedonia, Romania, Tunisia
-
Istituti Clinici Scientifici Maugeri SpARecruitingHeart Failure With Preserved Ejection Fraction | Heart Failure With Midrange Ejection FractionItaly
-
Milton S. Hershey Medical CenterWithdrawnHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Board of Trustees of Illinois State UniversityUniversity of Colorado, Denver; Abbott; University of North Carolina, Greensboro and other collaboratorsRecruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Milton S. Hershey Medical CenterCompletedHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Zhijun SunEnrolling by invitationHeart Failure | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection FractionChina
-
Corvia MedicalWithdrawnHeart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection Fraction
-
Occlutech International ABActive, not recruitingHeart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure With Reduced Ejection Fraction (HFrEF)United States
-
Yale UniversityRecruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure NYHA Class IVUnited States
Clinical Trials on Potassium Nitrate
-
University of PennsylvaniaCompleted
-
University of PennsylvaniaNorthwestern UniversityCompleted
-
University of PennsylvaniaCompletedHeart Failure | Diastolic Heart FailureUnited States
-
Washington University School of MedicineActive, not recruitingHeart FailureUnited States
-
GlaxoSmithKlineCompletedDentine HypersensitivityUnited States
-
Washington University School of MedicineRecruitingHeart FailureUnited States
-
Florida State UniversityCompleted
-
University of ReadingNot yet recruitingPost MenopausalUnited Kingdom
-
Karolinska InstitutetKarolinska University HospitalCompletedHypertension | Cardiovascular DiseaseSweden
-
Frank MoseHerning HospitalCompleted